^
Association details:
Biomarker:NF1 mutation
Cancer:Solid Tumor
Drug:Koselugo (selumetinib) (MEK inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Excerpt:
...NF1 mutation analysis will be performed on germline DNA as described by Messiaen & Wimmer 52....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma

Excerpt:
...- Patients be >= 18 years old at the time of enrollment and must have a documented germline neurofibromatosis 1 (NF1) mutation in a Clinical Laboratory Improvement Act (CLIA) certified laboratory or a diagnosis of NF1 based on clinical National Institutes of Health (NIH) consensus criteria; in addition to substantial cutaneous neurofibroma burden, at least one of the criteria below have to be present...
Trial ID:
More C2 evidence
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Excerpt:
...must have either a clinical diagnosis of NF1 or a germline NF1 mutation, or in patients without the NF1 syndrome, demonstrate an NF1 mutation in the GIST verified in a CLIA certified laboratory....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Selumetinib Pilot Study for Cutaneous Neurofibromas

Excerpt:
...- Patients must be ≥ 18 years old at the time of enrollment and have a documented germline NF1 mutation in a CLIA certified laboratory or a diagnosis of NF1 based on clinical NIH consensus criteria....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Excerpt:
...- - Patients must have a documented germline NF1 mutation in a CLIA certified laboratory or a diagnosis of NF1 based on clinical NIH consensus criteria51 of at least one other diagnostic criterion in addition to the presence of a PN. ...
Trial ID:
Less C2 evidence
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Selumetinib in patients with tumors with MAPK pathway alterations: Results from Arm E of the NCI-COG pediatric MATCH trial. Add to Collection

Published date:
05/19/2021
Excerpt:
Selumetinib did not result in tumor regression in this cohort of children and young adults with treatment-refractory tumors with activating MAPK pathway alterations. 
DOI:
10.1200/JCO.2021.39.15_suppl.10008
Trial ID: